Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP… Read more
Replimune Group Inc (REPL) - Net Assets
Latest net assets as of December 2025: $210.54 Million USD
Based on the latest financial reports, Replimune Group Inc (REPL) has net assets worth $210.54 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($333.59 Million) and total liabilities ($123.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $210.54 Million |
| % of Total Assets | 63.11% |
| Annual Growth Rate | N/A |
| 5-Year Change | -16.62% |
| 10-Year Change | N/A |
| Growth Volatility | 66.47 |
Replimune Group Inc - Net Assets Trend (2017–2025)
This chart illustrates how Replimune Group Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Replimune Group Inc (2017–2025)
The table below shows the annual net assets of Replimune Group Inc from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $415.84 Million | +11.04% |
| 2024-03-31 | $374.51 Million | -32.56% |
| 2023-03-31 | $555.29 Million | +35.03% |
| 2022-03-31 | $411.23 Million | -17.54% |
| 2021-03-31 | $498.73 Million | +171.46% |
| 2020-03-31 | $183.72 Million | +33.27% |
| 2019-03-31 | $137.86 Million | +591.15% |
| 2018-03-31 | $-28.07 Million | -143.75% |
| 2017-03-31 | $-11.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Replimune Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 93934900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $77.00K | 0.02% |
| Other Comprehensive Income | $5.45 Million | 1.31% |
| Other Components | $1.36 Billion | 326.78% |
| Total Equity | $415.84 Million | 100.00% |
Replimune Group Inc Competitors by Market Cap
The table below lists competitors of Replimune Group Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kunshan Top A Intelligent Equipment
SHE:300836
|
$398.83 Million |
|
Vitesco Technologies Group Aktiengesellschaft
PINK:VTSCY
|
$398.84 Million |
|
Tanzanian Royalty Exploration Corp
NYSE MKT:TRX
|
$398.94 Million |
|
Baolingbao Biology Co Ltd
SHE:002286
|
$398.99 Million |
|
Queclink Wireless Solutions Co Ltd
SHE:300590
|
$398.65 Million |
|
Wacker Neuson SE
PINK:WKRCF
|
$398.64 Million |
|
Lelon Electronics Corp
TW:2472
|
$398.57 Million |
|
Shandong Xiantan Co Ltd
SHE:002746
|
$398.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Replimune Group Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 374,508,000 to 415,843,000, a change of 41,335,000 (11.0%).
- Net loss of 247,297,000 reduced equity.
- New share issuances of 155,728,000 increased equity.
- Other comprehensive income increased equity by 593,000.
- Other factors increased equity by 132,311,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-247.30 Million | -59.47% |
| Share Issuances | $155.73 Million | +37.45% |
| Other Comprehensive Income | $593.00K | +0.14% |
| Other Changes | $132.31 Million | +31.82% |
| Total Change | $- | 11.04% |
Book Value vs Market Value Analysis
This analysis compares Replimune Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.36x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | $-0.37 | $7.00 | x |
| 2018-03-31 | $-0.91 | $7.00 | x |
| 2019-03-31 | $5.94 | $7.00 | x |
| 2020-03-31 | $5.36 | $7.00 | x |
| 2021-03-31 | $10.78 | $7.00 | x |
| 2022-03-31 | $7.88 | $7.00 | x |
| 2023-03-31 | $9.54 | $7.00 | x |
| 2024-03-31 | $5.63 | $7.00 | x |
| 2025-03-31 | $5.16 | $7.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Replimune Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.33x
- Recent ROE (-59.47%) is below the historical average (-27.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.55 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.90 Million |
| 2019 | -22.37% | 0.00% | 0.00x | 1.12x | $-44.62 Million |
| 2020 | -28.64% | 0.00% | 0.00x | 1.27x | $-71.00 Million |
| 2021 | -16.22% | 0.00% | 0.00x | 1.09x | $-130.74 Million |
| 2022 | -28.70% | 0.00% | 0.00x | 1.12x | $-159.16 Million |
| 2023 | -31.39% | 0.00% | 0.00x | 1.16x | $-229.81 Million |
| 2024 | -57.62% | 0.00% | 0.00x | 1.30x | $-253.24 Million |
| 2025 | -59.47% | 0.00% | 0.00x | 1.33x | $-288.88 Million |
Industry Comparison
This section compares Replimune Group Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Replimune Group Inc (REPL) | $210.54 Million | 0.00% | 0.58x | $398.83 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |